Opioid Growth Factor
Cross-source consensus on Opioid Growth Factor from 1 sources and 4 claims.
1 sources · 4 claims
How it works
Risks & contraindications
Evidence quality
Highlighted claims
- LDN's intermittent blockade of the OGF receptor leads to increased endogenous OGF production, which inhibits abnormal cell proliferation and promotes gut mucosal healing. — Low Dose Naltrexone: Menopause, Autoimmune Disease, and Inflammatory Modulation
- The OGF pathway is the only opioid receptor system involved in regulating cancer cell proliferation. — Low Dose Naltrexone: Menopause, Autoimmune Disease, and Inflammatory Modulation
- OGF levels are measurably lower in MS patients compared to non-MS patients, and LDN restored those levels. — Low Dose Naltrexone: Menopause, Autoimmune Disease, and Inflammatory Modulation
- High-dose naltrexone can paradoxically stimulate tumor growth, while low-dose intermittently inhibits OGF-receptor interaction to suppress abnormal cell replication. — Low Dose Naltrexone: Menopause, Autoimmune Disease, and Inflammatory Modulation